361 Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

361 Capital’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-12,666	Closed	-$43K	–	338
2017 Q3	$43K	Buy	+12,666	New	+$35.2K	0.01%	248

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

361 Capital's PDLI Position: Q4 2017 in Review

361 Capital sold out of PDL BioPharma, Inc. (PDLI) in Q4 2017, closing a stake of 12,666 shares — an estimated $43K sold.

361 Capital first reported a position in PDLI in Q3 2017 and held it in 1 quarter. The position peaked at $43K in Q3 2017. 187 funds tracked by Wall St. Rank hold PDLI as of Q4 2017.

361 Capital reported no remaining PDL BioPharma, Inc. position as of Q4 2017 after selling out during the quarter.
361 Capital sold 12,666 PDL BioPharma, Inc. shares in Q4 2017, an estimated $43K.
361 Capital first reported a position in PDL BioPharma, Inc. in Q3 2017 and held it in 1 quarter.
361 Capital's PDL BioPharma, Inc. position peaked at $43K in Q3 2017.
187 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2017.

Based on 361 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.